243984-11-4 Usage
Description
RESATORVID is a cell-permeable cyclohexenecarboxylate that selectively inhibits Toll-like receptor 4 (TLR4) signal transduction. It disrupts the interaction of TLR4 with adaptor molecules TIRAP and TRAM by directly binding to the TLR4 intracellular Cys747 residue. RESATORVID has been shown to effectively inhibit TLR4-mediated cellular events in vitro and prevent LPS-induced death in mice in vivo.
Uses
Used in Inflammation and Immune Response:
RESATORVID is used as an inhibitor of inflammatory mediators for reducing inflammation and modulating immune responses. It inhibits the production of nitric oxide (NO), tumor necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, IL-10, macrophage inhibitory protein (MIP)-2, and prostaglandin E2 from lipopolysaccharide (LPS)-stimulated macrophages.
Used in Pharmaceutical Industry:
RESATORVID is used as a selective TLR4 signal transduction inhibitor for the development of therapeutic agents targeting inflammatory diseases and conditions. Its ability to modulate the immune system and reduce inflammation makes it a promising candidate for drug development in this industry.
Biological Activity
toll, a member of the toll-like receptor (tlr) family, was identified as a gene product essential for the development of embryonic dorsoventral polarity in drosophila melanogaster. moreover, it has been also found to play a critical role in the antifungal response of flies. tak-242 (resatorvid), a cyclohexene derivative, is recongnizred as a novel small-molecule compound selectively inhibiting tlr4 signaling.
Biochem/physiol Actions
Cell permeable: yes
in vitro
a previous in-vitro study showed that tak-242 could inhibit the production of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of tlr4 using coimmunoprecipitation approach. among 10 different human tlrs, tak-242 selectively bound to tlr4. these findings suggested that tak-242 could selectively bind to tlr4 and disrupted the interaction of tlr4 with adaptor molecules, thereby inhibiting tlr4 signal transduction and its downstream signaling [2].
in vivo
preclinical animal study demonostrated that the acute restraint stress exposure upregulateed tlr-4 expression both at the mrna and protein level in rat. tak-242 pre-stress administration prevented the accumulation of potentially deleterious inflammatory and oxidative/nitrosative mediators in the brain frontal cortex of rats. these finding s indicated that the use of tak-242 or other tlr-4 signalling pathway inhibitory compounds could be considered as a potential therapeutic adjuvant strategy to constrain the inflammatory process taking place after stress exposure and in stress-related neuropsychiatric diseases [3].
IC 50
with ic50 of 1.1 to 11 nm, tak-242 inhibited lps-induced no production, tumor necrosis factor-alpha and interleukin (il)-6 in raw264.7 cells and mouse peritoneal macrophages [1].
references
[1] ii m, matsunaga n, hazeki k, nakamura k, takashima k, seya t, hazeki o, kitazaki t, iizawa y. a novel cyclohexene derivative, ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex- 1-ene-1-carboxylate (tak-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. mol pharmacol. 2006;69(4):1288-95. [2] naoko matsunaga, noboru tsuchimori, tatsumi matsumoto, and masayuki ii. tak-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (tlr) 4 signaling, binds selectively to tlr4 and interferes with interactions between tlr4 and its adaptor molecules. mol pharmacol 79:34–41, 2011. [3] iciar gárate, borja garcía-bueno, josé luis mu oz madrigal, javier r caso, luis alou, maría luisa gómez-lus and juan carlos leza. toll-like 4 receptor inhibitor tak-242 decreases neuroinflammation in rat brain frontal cortex after stress. journal of neuroinflammation 2014, 11:8.[4] todd w. rice; arthur p. wheeler; gordon r. bernard; jean-louis vincent; derek c. angus; naoki aikawa; ignace demeyer; stephen sainati; nicholas amlot; charlie cao; masayuki ii; hideyasu matsuda; kouji mouri; jon cohen. a randomized, double-blind, placebo-controlled trial of tak-242 for the treatment of severe sepsis. crit care med 2010 vol. 38, no. 8: 1-10.
Check Digit Verification of cas no
The CAS Registry Mumber 243984-11-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,3,9,8 and 4 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 243984-11:
(8*2)+(7*4)+(6*3)+(5*9)+(4*8)+(3*4)+(2*1)+(1*1)=154
154 % 10 = 4
So 243984-11-4 is a valid CAS Registry Number.
InChI:InChI=1/C15H17ClFNO4S/c1-2-22-15(19)11-5-3-4-6-14(11)23(20,21)18-13-8-7-10(17)9-12(13)16/h5,7-9,14,18H,2-4,6H2,1H3/t14-/m1/s1
243984-11-4Relevant articles and documents
Ex-vivo generation of drug-eluting islets improves transplant outcomes by inhibiting TLR4-Mediated NFkB upregulation
Chang, Charles A.,Akinbobuyi, Babatope,Quintana, Jeremy M.,Yoshimatsu, Gumpei,Naziruddin, Bashoo,Kane, Robert R.
, p. 13 - 24 (2018/01/10)
The systemic administration of immunosuppressive and anti-inflammatory drugs is routinely employed in organ transplantation to minimize graft rejection and improve graft survival. Localized drug delivery has the potential to improve transplant outcomes by providing sustained exposure to efficacious drug concentrations while avoiding systemic immunosuppression and off-target effects. Here, we describe the synthesis of a novel prodrug and its direct covalent conjugation to pancreatic islets via a cleavable linker. Post-transplant, linker hydrolysis results in the release of a potent anti-inflammatory antagonist of TLR4, localized to the site of implantation. This covalent islet modification significantly reduces the time and the minimal effective dose of islets necessary to achieve normoglycemia in a murine transplantation model. In streptozotocin-induced diabetic C57BL/6 mice a syngeneic transplant of ~100 modified islets achieved a 100% cure rate by the end of a 4-week monitoring period, compared to a 0% cure rate for untreated control islets. Overall, this direct prodrug conjugation to islets is well tolerated and preserves their functionality while affording significantly superior transplant outcomes. The development of drug-eluting tissues that deliver sustained and localized doses of small-molecule therapeutics represents a novel pathway for enhancing success in transplantation.
Convenient synthesis of antisepsis agent TAK-242 by novel optical resolution through diastereomeric N-acylated sulfonamide derivative
Nishiguchi, Atsuko,Ikemoto, Tomomi,Tomimatsu, Kiminori
, p. 4048 - 4051 (2007/10/03)
A convenient synthesis method of antisepsis agent TAK-242 ((R)-1) through diastereomeric resolution was developed. By condensation of racemate rac-1 with chiral acid (S)-O-acetylmanderic acid (6a), the desired diastereomer 5a was isolated with 98% de in 39% yield by simple crystallization. Deacylation of 5a with aq NaOH followed by recrystallization provided (R)-1 with 99% ee in 20% yield from rac-1.
Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate
Yamada, Masami,Ichikawa, Takashi,Ii, Masayuki,Sunamoto, Mie,Itoh, Katsumi,Tamura, Norikazu,Kitazaki, Tomoyuki
, p. 7457 - 7467 (2007/10/03)
To develop a new therapeutic agent for sepsis, screening of the Takeda chemical library was carried out using mouse macrophages stimulated with lipopolysaccharide (LPS) to identify a new class of small-molecule inhibitors of inflammatory mediator production. The lead compound 5a was discovered, from which a series of novel cyclohexene derivatives I bearing a sulfamoyl and ester group were designed, synthesized and tested for their inhibitory activity against nitric oxide (NO) production. Derivatives I were synthesized by the coupling of sulfonyl chlorides and anilines with concomitant double bond migration in the presence of triethylamine, and phenyl ring substitution and modification of the ester and cyclohexene moieties were carried out. Among the compounds synthesized, ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]- cyclohex-1-ene-1-carboxylate [(R)-(+)-5n, TAK-242] was found to exhibit the most potent suppressive activity for the production of not only NO but also inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) induced by LPS-stimulated mouse macrophages with IC 50 values of 1.8, 1.9 and 1.3 nM, respectively. It shows marked beneficial effects in vivo also. Intravenous administration of (R)-(+)-5n at doses of 0.1 mg/kg or more suppressed the production of NO and various cytokines [TNF-α, IL-6 and IL-1β] in the mouse endotoxin shock model. Furthermore, it protected mice from death dose-dependently and all mice survived at a dose of 3 mg/kg. The minimum effective dose to protect mice from lethality in this model was 0.3 mg/kg, which was consistent with those for inhibitory effects on the production of NO and cytokines. Compound CR)-(+)-5n is currently undergoing clinical trials for the treatment of sepsis.